Terms: = Breast cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Clinical Outcome
65 results:
1. High PD-L2 Predicts Early Recurrence of ER-Positive breast cancer.
Chervoneva I; Peck AR; Sun Y; Yi M; Udhane SS; Langenheim JF; Girondo MA; Jorns JM; Chaudhary LN; Kamaraju S; Bergom C; Flister MJ; Hooke JA; Kovatich AJ; Shriver CD; Hu H; Palazzo JP; Bibbo M; Hyslop T; Nevalainen MT; Pestell RG; Fuchs SY; Mitchell EP; Rui H
JCO Precis Oncol; 2023 Jan; 7():e2100498. PubMed ID: 36652667
[TBL] [Abstract] [Full Text] [Related]
2. Increased Co-Occurrence of Pathogenic Variants in Hereditary breast and Ovarian cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract] [Full Text] [Related]
3. Do patients' preferences prevail in hospital selection?: a comparison between discrete choice experiments and revealed hospital choice.
Salampessy BH; Ikkersheim D; Portrait FRM; Koolman X
BMC Health Serv Res; 2022 Sep; 22(1):1136. PubMed ID: 36076226
[TBL] [Abstract] [Full Text] [Related]
4. Phase II Study of Taselisib in
Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919
[TBL] [Abstract] [Full Text] [Related]
5. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic Utility of breast cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma.
Nunes R; Sella T; Treuner K; Atkinson JM; Wong J; Zhang Y; Exman P; Dabbs D; Richardson AL; Schnabel CA; Sgroi DC; Oesterreich S; Cimino-Mathews A; Metzger O
Clin Cancer Res; 2021 Oct; 27(20):5688-5696. PubMed ID: 34376532
[TBL] [Abstract] [Full Text] [Related]
7. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
[TBL] [Abstract] [Full Text] [Related]
8. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival outcome in Human Epidermal Growth Factor Receptor 2-positive Early breast cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract] [Full Text] [Related]
9. Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. clinical outcome and actionable molecular alterations.
Conforti F; Pala L; Pagan E; Rocco EG; Bagnardi V; Montagna E; Peruzzotti G; De Pas T; Fumagalli C; Pileggi S; Pesenti C; Marchini S; Corso G; Marchio' C; Sapino A; Graffeo R; Collet L; Aftimos P; Sotiriou C; Piccart M; Gelber RD; Viale G; Colleoni M; Goldhirsch A
Breast; 2021 Oct; 59():94-101. PubMed ID: 34217971
[TBL] [Abstract] [Full Text] [Related]
10. Effect of Exercise or Metformin on Biomarkers of Inflammation in breast and Colorectal cancer: A Randomized Trial.
Brown JC; Zhang S; Ligibel JA; Irwin ML; Jones LW; Campbell N; Pollak MN; Sorrentino A; Cartmel B; Harrigan M; Tolaney SM; Winer EP; Ng K; Abrams TA; Sanft T; Douglas PS; Hu FB; Fuchs CS; Meyerhardt JA
Cancer Prev Res (Phila); 2020 Dec; 13(12):1055-1062. PubMed ID: 32859615
[TBL] [Abstract] [Full Text] [Related]
11. Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study.
Huang CS; Yu AL; Tseng LM; Chow LWC; Hou MF; Hurvitz SA; Schwab RB; L Murray J; Chang HK; Chang HT; Chen SC; Kim SB; Hung JT; Ueng SH; Lee SH; Chen CC; Rugo HS
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32718986
[TBL] [Abstract] [Full Text] [Related]
12. Exposure-response analysis of endoxifen serum concentrations in early-breast cancer.
Sanchez-Spitman AB; Moes DAR; Swen JJ; Dezentjé VO; Lambrechts D; Neven P; Gelderblom H; Guchelaar HJ
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1141-1152. PubMed ID: 32468081
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of Abbreviated breast MRI vs Digital breast Tomosynthesis for breast cancer Detection Among Women With Dense breasts Undergoing Screening.
Comstock CE; Gatsonis C; Newstead GM; Snyder BS; Gareen IF; Bergin JT; Rahbar H; Sung JS; Jacobs C; Harvey JA; Nicholson MH; Ward RC; Holt J; Prather A; Miller KD; Schnall MD; Kuhl CK
JAMA; 2020 Feb; 323(8):746-756. PubMed ID: 32096852
[TBL] [Abstract] [Full Text] [Related]
14. Influence of pre-operative oral carbohydrate loading vs. standard fasting on tumor proliferation and clinical outcome in breast cancer patients ─ a randomized trial.
Lende TH; Austdal M; Varhaugvik AE; Skaland I; Gudlaugsson E; Kvaløy JT; Akslen LA; Søiland H; Janssen EAM; Baak JPA
BMC Cancer; 2019 Nov; 19(1):1076. PubMed ID: 31703648
[TBL] [Abstract] [Full Text] [Related]
15. clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients.
Banys-Paluchowski M; Milde-Langosch K; Fehm T; Witzel I; Oliveira-Ferrer L; Schmalfeldt B; Müller V
Breast Cancer Res Treat; 2020 Jan; 179(2):403-414. PubMed ID: 31646390
[TBL] [Abstract] [Full Text] [Related]
16. Molecular Characterization and clinical Relevance of Metabolic Expression Subtypes in Human cancers.
Peng X; Chen Z; Farshidfar F; Xu X; Lorenzi PL; Wang Y; Cheng F; Tan L; Mojumdar K; Du D; Ge Z; Li J; Thomas GV; Birsoy K; Liu L; Zhang H; Zhao Z; Marchand C; Weinstein JN; ; Bathe OF; Liang H
Cell Rep; 2018 Apr; 23(1):255-269.e4. PubMed ID: 29617665
[TBL] [Abstract] [Full Text] [Related]
17. Oestrogen receptor negative early operable primary breast cancer in older women-Biological characteristics and long-term clinical outcome.
Syed BM; Morgan D; Setty T; Green AR; Paish EC; Ellis IO; Cheung KL
PLoS One; 2017; 12(12):e0188528. PubMed ID: 29284000
[TBL] [Abstract] [Full Text] [Related]
18. Reirradiation + hyperthermia for recurrent breast cancer en cuirasse.
Oldenborg S; Rasch CRN; van Os R; Kusumanto YH; Oei BS; Venselaar JL; Heymans MW; Zum Vörde Sive Vörding PJ; Crezee H; van Tienhoven G
Strahlenther Onkol; 2018 Mar; 194(3):206-214. PubMed ID: 29264624
[TBL] [Abstract] [Full Text] [Related]
19. Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
Sheri A; Smith IE; Hills M; Jones RL; Johnston SR; Dowsett M
Breast Cancer Res Treat; 2017 Jul; 164(2):395-400. PubMed ID: 28447240
[TBL] [Abstract] [Full Text] [Related]
20. Automated telephone communication systems for preventive healthcare and management of long-term conditions.
Posadzki P; Mastellos N; Ryan R; Gunn LH; Felix LM; Pappas Y; Gagnon MP; Julious SA; Xiang L; Oldenburg B; Car J
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD009921. PubMed ID: 27960229
[TBL] [Abstract] [Full Text] [Related]
[Next]
